Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
FDA concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration. Content current through May 31, 2026.
Bachem: peptide notation and terminal modifications
Bachem: peptide notation and terminal modifications. Accessed 2026-10-03.
Bachem: Quality Control of Amino Acids and Peptides
Bachem: Quality Control of Amino Acids and Peptides. Accessed 2026-10-05.
Original publication PMID 39555826
Checked 2026-10-06; original study, not NHD batch evidence.
Original publication PMID 38912654
Checked 2026-10-06; original study, not NHD batch evidence.
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
MOUNJARO (tirzepatide) current prescribing information
U.S. Food and Drug Administration. Revised December 2025. Initial U.S. approval 2022.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
N Engl J Med. 2025. PMID 40544433.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
N Engl J Med. 2025. PMID 40544432.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
ZEPBOUND (tirzepatide) prescribing information
U.S. Food and Drug Administration. Current Drugs@FDA label for NDA 217806.
Care and handling of peptides
Care and handling of peptides
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
Receptor Binding Assays for HTS and Drug Discovery
Receptor Binding Assays for HTS and Drug Discovery
Solubility Guidelines for Peptides
Solubility Guidelines for Peptides
Research news reference — www.lilly.com — news-07
Technical reference — www.novonordisk.com — news-details.html
Research news reference — www.novonordisk.com — news-04
Research news reference — www.novonordisk.com — news-03
Primary publication — PubMed 39996356
Primary publication — PubMed 40832789
ICH Q2(R2) Validation of Analytical Procedures
ICH Q2(R2) Validation of Analytical Procedures
SURPASS-1 randomized phase 3 trial
Primary clinical trial record; PMID 34186022.
Tirzepatide receptor imbalance and signaling bias
Tirzepatide receptor imbalance and signaling bias
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records
